Peripheral stenting
Devicestent implantation during the index procedure
NCT Number: NCT03037411
The REGAL study is a European, prospective, multi-center Post-Market Clinical Follow-up (PMCF) trial providing additional data including health economics data to support the use of the ELUVIA stent in the treatment of lesions located in the femoropopliteal arteries.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Medizinische Universität Graz, Graz, Austria
A European, prospective, multi-center Post-Market Clinical Follow-up (PMCF) trial providing additional data including health economics data to support the use of the ELUVIA stent in the treatment of lesions located in the femoropopliteal arteries.
The objective of the study is to collect additional data including health economics data to support the use of the ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
stent implantation during the index procedure
Time frame: Baseline,12 and 24 months
The EQ-5D assesses five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) of health-related quality of life responses assigned by the participants. The values are anchored at 1 (best) to 0 (worst). The vales for the visual analog score takes values from 100 (best) to 0 (worst). The index value is comparable across the baseline, 12- and 24-Months timepoints.
Time frame: 12 and 24 months
Improvement was calculated by comparing the scores from 12- and 24-Months to the baseline scores and presenting the number of participants that showed improvement at 12- and 24-Months. The WIQ measures the improvement as reported by participants in their walking distance, walking speed, stair-climbing ability and improvement in their PAD symptoms pre-procedure (baseline) compared to 12 months and compared to 24 months. The improvement at those time points is measured as percent improvement.
Time frame: 12 and 24 months
The Rutherford Classification describes the different stages of peripheral artery disease (PAD) from a score of 0 (no PAD) to 6 (critical limb ischemia with major tissue loss). The percentages represent the percent of participants that had sustained clinical improvement from baseline to 12 months and baseline to 24 months. Sustained clinical improvement means their Rutherford Class improved by one or more categories compared with baseline.
Number of participants with improved Rutherford Classification at 12- and 24-Months when compared to baseline.
Primary Sustained Clinical Improvement is improvement in Rutherford Classification of one or more categories as compared to baseline without the need for repeat target lesion revascularization (TLR).
Secondary Sustained Clinical Improvement is improvement in Rutherford classification of one or more categories as compared to baseline including those participants with repeat TLR.
Time frame: 12 and 24 months
Number of participants with improvement in Ankle-Brachial Index (ABI) at 12- and 24-Months compared to baseline.
Hemodynamic Improvement is defined as an increase in ABI of >= 0.10 or to an ABI >= 0.90 as compared to baseline without the need for repeat TLR. The ABI measures the arterial pressure in the leg compared to the arterial pressure in the arm. The higher the value, the better the blood flow. Improvement is defined as an increase in the ABI by greater than or equal to 0.10 compared with baseline or to an ABI greater than or equal to 0.90. The percentages in the table represent the patients that demonstrated an improvement in their ABI from baseline to 12 months and baseline to 24-months.
Time frame: 1, 6, 12 and 24 months
Changes in healthcare utilization over time
Time frame: During stenting procedure
Number of participants that successfully received Eluvia stent. Technical success defined as implanted and achieving residual angiographic stenosis no greater than 30% assessed visually.
Time frame: within 24 hours of stenting procedure
Number of participants with successful procedures. Procedural success defined as technical success with no major adverse events (MAEs) noted within 24 hours of the stenting procedure.
Time frame: 12 and 24 months
Number of participants with Clinical Events Committee (CEC) adjudicated MAEs at 12- and 24-Months cumulatively. The MAEs are defined as all causes of death, target limb major amputation and/or Target Lesion Revascularization rate. A participant can be present in more than one sub-category.
Time frame: 12 and 24 months
The numbers represent the percentage of patients that were event free at 12 and 24 months (i.e. didn't have a TLR).
Time frame: 12 and 24 months
The cumulative number of participants that received a clinically-driven target lesion revascularization after the stenting procedure.
Time frame: 12 and 24 months
The cumulative number of participants that received a clinically-driven target vessel revascularization after the stenting procedure.
Time frame: Baseline, 12 and 24 months
Rutherford Classification:
Boston Scientific Corporation
Industry
A Real World Evaluation of the ELUVIA Drug Eluting Stent in All-Comers With Superficial Femoral Artery and Proximal Popliteal Artery Disease
Acronym: REGAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02921230
Arterial Occlusive Diseases, Arteriosclerosis
Innsbruck, Austria
View Trial DetailsNCT03898570
Arterial Occlusive Diseases, Arteriosclerosis
Palo Alto, California, United States
View Trial DetailsNCT03856606
Arterial Occlusive Diseases, Arteriosclerosis
Austin, Texas, United States
View Trial DetailsNCT04624854
Acute Coronary Syndrome, Arterial Occlusive Diseases
Chongqing, Chongqing Municipality, China
View Trial Details